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Aims Moststudiesontheprimarypreventionofcardiovasculardisease(CVD)havebeenlimitedtopatientsathighCVDrisk.We
assessedthe achievement oftreatment goals for CVD risk factors among patients with a substantialvariationin CVD risk.
Methods
and results
This study was conducted with 7641 outpatients aged ≥50 years, free of clinical CVD and with at least one major
CVD risk factor, selected from 12 European countries in 2009. Risk factor deﬁnition and treatment goals were based
on the 2007 European guidelines on CVD prevention. Cholesterol fractions and glycated haemoglobin (HbA1c) were
measured in a central laboratory. Cardiovascular disease risk was estimated with the SCORE equation. Patients’ mean
age was 63 years (48% men), and 40.1% had a high CVD risk. Among treated hypertensives (94.2%), only 38.8%
achieved the blood pressure target of ,140/90 mmHg [between-country range (BCR): 32.1–47.5%]. Among
treated dyslipidaemic patients (74.4%), 41.2% attained both the total- and LDL-cholesterol target of ,5 and
,3 mmol/L, respectively (BCR: 24.3–68.4%). Among treated type 2 diabetic patients (87.2%), 36.7% achieved the
,6.5% HbA1c target (BCR: 23.4–48.4%). Among obese patients on non-pharmacological treatment (92.2%),
24.7% reached the body mass index target of ,30 kg/m
2 (BCR: 12.7–37.1%). About one-third of controlled patients
on treatment were still at high remaining CVD risk. Although most patients were advised to reduce excess weight and
to follow a low-calorie diet, less than half received written recommendations.
Conclusions In Europe, a large proportion of patients in primary prevention have CVD risk factors that remain uncontrolled, and
lifestyle counselling is not well implemented; moreover, there is substantial between-country variation, which indi-
cates additional room for improvement. Raised residual CVD risk is relatively frequent among patients despite
control of their primary risk factors and should be addressed.
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Despite compelling evidence for the efﬁcacy of primary preven-
tion,
1–3 cardiovascular disease (CVD) remains the main cause of
mortality in Europe.
2,4 One important reason could be the insufﬁ-
cient implementation of evidence-based CVD prevention guide-
lines.
2 Some country-speciﬁc studies, mostly conducted in
high-risk patients, have shown that control of CVD risk factors is
sub-optimal despite widespread treatment
5–12 but the few multi-
national surveys available have focused on single risk factors,
13,14
did not directly measure risk factors at the study visit,
15 or were
limited to patients with pre-existing CVD or at high or very high
risk of CVD.
16–19 Hence, there is limited comparable information
on management and control of CVD risk factors in primary pre-
vention patients over a wider range of global CVD risk across
Europe. These patients, however, comprise a large fraction of all
patients attended in primary care and, because of their large
number, give rise to a large proportion of CVD events in the
population.
20
In order to provide a comprehensive assessment of clinical prac-
tice in the primary prevention of CVD across Europe, we studied
patients with major CVD risk factors but with varying degrees of
CVD risk. In these patients, we assessed the achievement of treat-
ment goals for the main CVD risk factors. We also estimated these
patients’ residual risk on treatment, determined by the SCORE
equation.
21–23 The SCORE equation for estimating CVD risk is a
central element in the European prevention guidelines, but it has
yet not been used in any major international study.
Methods
Study design and participants
The European Study on Cardiovascular Risk Prevention and Manage-
ment in Usual Daily Practice (EURIKA)
24 was a cross-sectional study
conducted simultaneously in 12 European countries (Austria,
Belgium, France, Germany, Greece, Norway, Russia, Spain, Sweden,
Switzerland, Turkey, and the UK; ClinicalTrials.gov identiﬁer,
NCT00882336). These countries were selected to represent the com-
plete spectrum of CVD risk across Europe, as well as a variety of differ-
ent healthcare systems. Data collection started in May 2009 and ended
in January 2010.
Participating physicians were selected to represent practitioners
involved in CVD prevention in primary care centres or outpatient
clinics in each country. OneKey, a large database containing
information on the characteristics of practicing physicians (http://
crm.cegedim.com/solutions/data/Pages/default.aspx) served as the
sampling frame. Directories of health centres, drawn from ofﬁcial
webs, registries, and addresses of health administrations and pro-
fessional organizations in the public and private sectors, were used
to make up the physicians panel or universe of doctors potentially par-
ticipating in the study. A total of 399 298 physicians are included in the
OneKey database for the 12 countries considered (9848 in Austria,
12 588 in Belgium, 69 173 in France, 74963 in Germany, 11 699 in
Greece, 6181 in Norway, 54 592 in Russia, 59 266 in Spain, 8740 in
Sweden, 8093 in Switzerland, 39 825 in Turkey, and 44 330 in UK).
A total of 226 290 were men (56.7%) and 173 008 women (43.3%).
Onekey was used to select a random sample of physicians stratiﬁed
by age, sex, and specialty, including family medicine and other
medical specialties involved in CVD risk factor control, such as cardi-
ology, internal medicine, and endocrinology. Physician sex and age
strata were proportional to their distribution in the OneKey database.
A total of 809 physicians ( 60 per country) participated in EURIKA.
About 64% of them were general/primary care practitioners. The per-
centage of participating physicians among those invited was 7.4% in
Austria, 13.8% in Belgium, 10.8% in France, 8.0% in Germany, 14.5%
in Greece, 8.5% in Norway, 6.3% in Spain, 3.1% in Sweden, 3.4% in
Switzerland, 22.8% in Turkey, 6.6% in the UK.
Selection criteria for patients were being 50 years of age or older,
free from clinical CVD, and with at least one of the classic CVD risk
factors (hypertension, dyslipidaemia, diabetes, obesity, or tobacco con-
sumption documented in the clinical record). Physicians were given a
randomisation list to select a sample of patients cited for medical
visit each day during the study period. Approximately 12 300 patients
were invited to participate, of whom 7641 (62%) accepted.
The study protocol was approved by the appropriate clinical
research Ethics Committee in each participating country. All patients
provided written informed consent.
Assessment of cardiovascular disease
risk factors
Patient information was collected from clinical records, and from an ad
hoc standardized interview, a physical exam, and a fasting blood sample.
Information on smoking and physical activity was obtained from patient
interviews. Hypertension, dyslipidaemia, diabetes, and obesity were
considered present if their diagnosis was documented in the medical
record. The prescription of speciﬁc medical advice for hypertension,
dyslipidaemia, diabetes, obesity, and smoking was ascertained by ques-
tionnaire addressed to the physician.
Physical examination included height and weight measurement using
calibrated scales and stadiometers, with participants wearing light
clothing and without shoes.
2,24 Waist circumference (WC) was
measured to the nearest 0.1 cm, at the midpoint between the
lowest rib and the iliac crest with patients unclothed to the waist.
Blood pressure (BP) was determined in standardized conditions,
using calibrated mercury sphygmomanometers or validated automated
devices, and appropriate-size cuffs.
2,24 The average of three readings
was used for analyses.
A 12 h fasting blood sample was obtained on the day of physical
examination or, if not possible, on the following day. Blood samples
were sent to a central laboratory in Belgium for the analysis (The
Bio Analytical Research Corporation, www.barclab.com). High-density
lipoprotein cholesterol was measured by a modiﬁed enzymatic method
(Roche P-Modular analyzer), total cholesterol by the CHOD-PAP
method (Roche P-Modular), triglycerides by the GPO-PAP method
(Roche P-Modular), and low-density lipoprotein cholesterol was calcu-
lated by the Friedewald formula. Glycosylated haemoglobin (HbA1c)
was measured by ion-exchange (high-performance liquid chromato-
graphy/Menarini 8160).
In each country, a 10% random sample of all study centres under-
went a site visit for data monitoring and audit to ensure data quality.
Treatment goals for cardiovascular disease
risk factors
Treatment goals were evaluated in accordance with the Fourth Euro-
pean guidelines based on data from the physical examination or from
the blood sample drawn at the study visit.
2 Target BP was systolic/
diastolic (SBP/DBP) ,140/90 mmHg, except for patients with
diabetes where it was ,130/80 mmHg. Target lipid levels were
,5 mmol/L (190 mg/dL) total cholesterol and ,3 mmol/L (115 mg/
J.R. Banegas et al. 2144dL) LDL-cholesterol, except for patients with diabetes where the goal
was ,4.5 mmol/L (175 mg/dL) total cholesterol, and ,2.5 mmol/L
(100 mg/dL) LDL-cholesterol. The target HbA1c was ,6.5%, and
the target fasting plasma glucose (FPG) was ,6.1 mmol/L (110 mg/
dL) in all patients. The target body mass index (BMI) was ,30 kg/m
2
and the target WC was ,102 cm in men and ,88 cm in women.
We calculated the 10 year risk of fatal CVD for each patient using
the SCORE equation, based on age, sex, current smoking, total choles-
terol, and SBP measured at the study visit. These values were indepen-
dent of treatment. We used the equation developed for low-risk
regions for patients in Belgium, France, Greece, Spain, and Switzerland,
and the equation for high-risk regions for patients in Austria, Germany,
Norway, Russia, Sweden, Turkey, and the UK.
2,4,21,22 A 10 year risk of
CVD death ≥5% was regarded as high CVD risk.
2,25
Statistical analyses
The main outcome was the proportion of patients achieving treatment
goals. Generalized mixed linear models were used to identify clinical
variables associated with attainment of treatment goals for CVD risk
factors. Regression models included sex, age, smoking, hypertension,
dyslipidaemia, diabetes, obesity, physical inactivity, and country
(random effect variable). Also, control of CVD risk factors in each
country was compared with the average across participating countries,
using logistic regression models adjusted for sex and age. All variables
were modelled as categorical with dummy terms. Statistical signiﬁcance
was set at two-tailed P , 0.05. Analyses were performed with the SAS
system (version 9.1, SAS Institute, Inc., Cary, NC, USA).
Results
The average (SD) age of participating patients was 63.2 (+8.9)
years. Also, 48.4% of participants were men, 48.4% had a history
of smoking (21.3% current smokers), 72.7% had hypertension,
57.7% had dyslipidaemia, 26.8% had type 2 diabetes, 43.6% were
obese, 19.8% were physically inactive, and 50.2% did light physical
activity only (activity during most weeks, not causing shortness of
breath, increased heart rate and perspiration) (Table 1). About 40%
of patients was at high CVD risk despite being or not being treated,
with a between-country range (BCR) of 29–57.3% (Table 1).
Achievement of treatment goals
Among 5559 patients with hypertension, 94.2% were on antihyper-
tensive drugs. Target BP was reached by 38.8% of treated patients
(BCR: 32.1–47.5%) (Table 2).
Of 4407 patients with dyslipidaemia, 74.4% were treated with
lipid-lowering drugs. Target total cholesterol and LDL-cholesterol
levels were reached by 41.2% of treated patients (BCR: 24.3–
68.4%) (Table 2). The proportion of patients attaining the total
cholesterol target alone was 43.3% (BCR: 27.6–70.8%).
Among 2046 patients with type 2 diabetes, 87.2% were treated
with antidiabetic drugs. The recommended HbA1c level of ,6.5%
was reached by 36.7% of treated patients (BCR: 23.4–48.4%)
(Table 2). In addition, 20% of treated patients achieved the target
FPG of ,6.1 mmol/L (BCR: 6.0–43.1%). Only 7.2% of treated
patients with diabetes achieved both their target FPG and
HbA1c levels.
Of 3324 patients with a diagnosis of obesity prior to study enrol-
ment, 92.2% were on lifestyle treatment (weight reduction advice)
(Table 2). The target of BMI ,30 kg/m
2 was reached by 24.7% of
these patients (BCR: 12.7–37.1%). In addition, 6.8% of patients
achieved a WC ,102 cm (men) or ,88 cm (women) (BCR:
2.2–12.0%), and only 3.2% of patients attained both BMI and
WC goals (BCR: 0.4–6.0%).
Finally, the percentage of treated patients with 1, 2, or the 3
main CVD risk factors (hypertension, dyslipidaemia, diabetes) at
goal was 41.3, 18.6, and 3.7%, respectively.
Remaining cardiovascular disease risk
in patients achieving treatment goals
Among the 2032 hypertensive patients with BP controlled on drug
treatment, 34.8% remained at high CVD risk (Table 3). Likewise,
39.2% of the 1350 controlled dyslipidaemic patients, 38% of the
655 controlled diabetic patients, and 39% of the 738 controlled
obese patients also still had a high residual CVD risk, with wide
between-country ranges.
Lifestyle medical advice
Almost 89% of smokers were asked about their smoking habit, but
only 64% had their degree of addiction assessed, and as few as
38.8% agreed on a smoking cessation strategy (Table 4). Weight
reduction was the medical advice most frequently given to obese
patients. Advice on a healthy diet (low in fat and rich in vegetables
and fruit) was provided to .80% of patients, but only half of them
were given written dietary advice and as few as one-quarter to
one-third was referred to a dietician. Appropriate advice on phys-
ical activity (at least 30 min, with moderate or vigorous intensity,
on most days of the week) was given to  80% of physically inac-
tive patients. Between-country range in lifestyle medical advice
was wide.
Variables associated with achievement
of treatment goals
Female patients were less likely to achieve risk factor goals in dys-
lipidaemia and men less likely to attain their BP goal (Table 5).
Patients over 65 years were more likely to achieve control of dys-
lipidaemia and obesity. Control of hypertension was much lower in
diabetic patients and in those with obesity. Control of diabetes was
lower in dyslipidaemic patients, and control of obesity was lower in
those with hypertension, diabetes, and physical inactivity. Lastly,
countries in Eastern Europe showed generally lower than
average attainment of treatment goals for most CVD risk factors
(Table 6).
Discussion
Principal ﬁndings
The EURIKA study is the ﬁrst to attempt a large-scale compara-
tive assessment of the status of primary CVD prevention among
patients with varying degrees of CVD risk across Europe. Its
main ﬁnding was that, currently in 2010, the control of CVD
risk factors in primary prevention is generally poor. Less than
half of hypertensive and dyslipidaemic patients attained treatment
goals, and only one-third of patients with diabetes met the
HbA1c goal. We also observed that the no-smoking advice
was the least frequently provided professional advice, that
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Table 1 Socio-demographic and clinical characteristics of patients in the EURIKA study, by country
AUS
(n 5 624)
BEL
(n 5 638)
FRA
(n 5 593)
GER
(n 5 678)
GRE
(n 5 620)
NOR
(n 5 611)
RUS
(n 5 604)
SPA
(n 5 642)
SWE
(n 5 628)
SWI
(n 5 667)
TUR
(n 5 663)
UK
(n 5 673)
Total
(n 5 7641)
Age, mean+SD 61.9+8.6 64.6+8.9 64.1+8.8 65.3+8.8 65.3+8.9 62.9+8.5 58.3+7.3 63.1+9.0 64.9+8.6 65.2+9.9 59.4+7.6 65.0+8.9 63.2+8.9
Men, % 47.6 48.9 54.8 49.1 46.0 48.8 31.8 51.4 50.2 52.8 47.2 51.1 48.4
Smoking,% 50.4 39.8 43.5 47.9 51.6 63.0 40.6 41.7 51.0 49.9 46.9 53.7 48.4
Current
smokers,%
23.8 16.2 16.5 16.5 33.9 28.1 25.2 17.2 16.9 21.5 23.7 16.4 21.3
Former
smokers,%
26.6 23.6 27.0 31.3 17.7 34.9 15.4 24.5 34.0 28.4 23.2 37.2 27.1
Hypertension,% 71.6 70.2 73.2 81.0 66.6 69.7 80.5 67.8 82.2 71.2 66.5 72.7 72.7
Dyslipidaemia,% 59.0 68.0 56.7 59.6 72.6 54.8 50.5 67.3 49.8 59.1 34.5 60.5 57.7
Type 2 diabetes
mellitus,%
23.4 27.1 24.3 37.8 28.4 23.2 15.7 28.3 26.1 30.7 31.7 22.7 26.8
Obesity,% 50.7 49.5 36.7 49.0 50.2 36.8 56.6 40.2 37.5 45.3 36.2 35.5 43.5
Physical
inactivity,%
16.5 29.5 32.9 12.1 30.8 16.5 12.6 22.6 5.9 20.5 28.3 9.8 19.8
Light physical
activity,%
54.5 48.3 38.5 51.5 43.3 51.1 54.6 46.5 50.6 50.5 52.1 60.1 50.2
High
cardiovascular
disease risk,%
43.1 31.2 29.5 57.1 27.3 51.5 29.0 29.1 57.3 36.9 33.6 53.8 40.1
AUS, Austria; BEL, Belgium; FRA, France; GER, Germany; GRE, Greece; NOR, Norway; RUS, Russia; SPA, Spain; SWE, Sweden; SWI, Switzerland; TUR, Turkey; UK, United Kingdom; SD, standard deviation. Calculation of SCORE risk was
based on the following data: age, sex, systolic blood pressure and total cholesterol values at the study visit, and smoking status.
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6many patients were not given written dietary counselling, and
that only a small proportion of patients achieved a satisfactory
BMI and WC.
Although high-risk patients are the top priority in CVD preven-
tion,
2 lower-global risk patients with important individual risk
factors comprise a numerically important segment (60%) of the
EURIKA population. These patients may beneﬁt from both
population strategies and speciﬁc interventions.
26 Therefore, life-
style changes should be encouraged and implemented more effec-
tively in these patients.
There were a substantial proportion of patients at high remain-
ing CVD risk (35–39% for the different individual risk factors)
among those who achieved speciﬁc treatment goals. This is due
to presence of risk factors in addition to the main one under
...............................................................................................................................................................................
Table 2 Achievement of goals among patients treated for the main cardiovascular risk factors, by country
AUS BEL FRA GER GRE NOR RUS SPA SWE SWI TUR UK Total, n (%)
Hypertension, n 447 448 434 549 413 426 486 435 516 475 441 489 5559
Drug treated,% 92.8 96.4 97.2 97.3 97.3 90.1 85.4 92.4 96.3 95.2 94.6 95.5 94.2
Controlled (SBP ,140 mmHg
and DBP ,90 mmHg),%
a
35.9 43.7 45.5 36.3 47.5 34.6 35.9 41.0 33.6 37.4 32.1 42.8 38.8
Dyslipidaemia, n 368 434 336 404 450 335 305 432 313 394 229 407 4407
Drug treated,% 58.7 75.1 81.2 65.1 80.2 75.5 49.8 81.2 85.9 74.6 80.3 82.6 74.4
Controlled (TC ,5 mmol/L),%
a 32.9 54.6 39.9 33.5 39.1 45.8 27.6 32.8 48.0 45.9 30.4 70.8 43.3
Controlled (TC ,5 mmol/L
and LDL-c ,3 mmol/L),%
a
31.9 52.8 37.7 30.4 37.4 41.9 24.3 31.0 45.3 44.6 30.4 68.4 41.2
Type 2 diabetes, n 146 173 144 256 176 142 95 182 164 205 210 153 2046
Drug treated,% 86.3 90.7 93.7 80.9 92.0 82.4 84.2 87.9 83.5 89.8 95.2 77.8 87.2
Controlled (HbA1c ,6.5%),% 39.7 48.4 41.5 40.6 43.8 41.9 26.2 33.7 23.4 41.8 26.0 27.7 36.7
Controlled (FPG ,6.1 mmol/L),% 16.7 19.7 27.4 27.0 15.4 35.9 7.5 13.1 43.1 16.3 6.0 13.4 20.0
Controlled (HbA1c ,6.5%
and FPG ,6.1 mmol/L), %
7.9 6.4 6.7 11.1 8.0 15.4 3.7 3.1 10.9 8.1 2.5 1.7 7.2
Obesity, n 315 315 217 332 311 224 342 256 235 298 240 239 3324
Treatment with lifestyle advice,% 91.7 91.7 98.2 94.6 94.5 86.2 97.7 97.6 72.3 88.6 96.2 94.1 92.2
Controlled (BMI ,30 kg/m
2),% 28.0 29.2 19.6 28.8 37.1 26.7 23.3 21.1 23.3 23.8 16.1 12.7 24.7
Controlled (WC ,102/88 cm),% 6.2 12.0 2.9 9.0 7.6 4.9 5.9 11.2 3.6 7.0 2.2 5.2 6.8
Controlled (BMI ,30 kg/m
2
and WC ,102/88 cm),%
3.2 6.0 2.4 5.3 4.1 2.7 0.9 4.1 2.4 3.8 0.4 1.4 3.2
AUS, Austria; BEL, Belgium; FRA, France; GER, Germany; GRE, Greece; NOR, Norway; RUS, Russia; SPA, Spain; SWE, Sweden; SWI, Switzerland; TUR, Turkey; UK, United
Kingdom; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol;LDL-c, low density lipoprotein cholesterol; HbA1c, glycated haemoglobin; FPG, fasting
plasma glucose; BMI, body mass index; WC, waist circumference.
aIf diabetes: blood pressure ,130/80 mmHg, total cholesterol ,4.5 mmol/L, and LDL cholesterol ,2.5 mmol/L.
.................................. ................................ ................................ ................................
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Table 3 Remaining cardiovascular risk in patients achieving treatment goals
Hypertension Dyslipidaemia Type 2 diabetes Obesity
High risk Low risk High risk Low risk High risk Low risk High risk Low risk
All countries
Treated and controlled
a
Number 707 1325 529 821 249 406 288 450
Percentage 34.8 65.2 39.2 60.8 38.0 62.0 39.0 61.0
Between-country range
Treated and controlled
a
Percentage 20.3–45.0 50.0–79.7 19.6–57.5 46.2–80.4 19.6–59.4 40.6–80.4 24.1–59.3 40.7–75.9
Calculation of SCORE risk was based on the following data: age, sex, systolic blood pressure and total cholesterol values at the study visit, and smoking status.
aHypertension control: blood pressure ,140/90 mmHg (,130/80 mmHg if diabetes). Dyslipidaemia control: total cholesterol ,5 mmol/L and LDL cholesterol ,3 mmol/L
(if diabetes: ,4.5 and ,2.5 mmol/L, respectively). Diabetes control: HbA1c ,6.5%. Obesity control: body mass index ,30 kg/m
2.
EURIKA study 2147consideration. For example, among dyslipidaemic patients with
LDL at goal, BP or smoking status is frequently not at target, or
HDL cholesterol may not be within satisfactory limits.
23 Thus,
despite effective statin treatment, multifactorial lifestyle and,
where appropriate, pharmacological measures are clearly needed
to address this appreciable level of residual risk.
Reasons for not achieving treatment goals
In multivariate analyses, treated diabetes and obesity were associ-
ated with poor control of hypertension, in line with previous
studies.
27 Despite most obese patients receiving medical advice
to follow a low-calorie diet and try to lose weight, many were
likely not to comply, which may partly account for the low rate
.....................................
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Table 4 Medical advice on lifestyle among patients with cardiovascular risk factors
All countries Between-country range
n %%
Tobacco smoking (n ¼ 3652)
Ask about tobacco smoking,% 3212 88.7 67.6–96.8
Assess degree of addiction,% 2291 64.0 44.0–84.7
No-smoking advice,% 2435 68.0 46.7–83.9
Smoking cessation strategy,% 1389 38.8 22.6–71.1
Hypertension (n ¼ 5559)
No-smoking advice,% 1501 63.0 44.5–77.5
Salt reduction advice,% 4070 74.0 45.2–99.0
Alcohol reduction advice,% 2557 46.5 25.6–66.1
Healthy diet advice,% 4575 82.5 53.3–98.5
Written dietary advice,% 2405 52.7 24.0–83.9
Referred to a dietitian/nutritionist,% 971 21.3 12.7–41.8
Weight reduction advice (if BMI ≥30),% 2419 92.5 73.4–98.2
Physical activity advice (if no or light PA), % 850 79.7 56.5–96.7
Dyslipidaemia (n ¼ 4407)
No-smoking advice,% 1344 65.8 54.3–83.3
Healthy diet advice,% 3753 85.5 69.2–98.4
Written dietary advice,% 2141 57.3 27.9–88.6
Referred to a dietitian/nutritionist,% 820 21.9 13.2–46.3
Weight reduction advice (if BMI ≥30),% 1882 92.5 86.2–98.5
Physical activity advice (if no or light PA), % 694 80.5 61.0–97.0
Type 2 diabetes (n ¼ 2046)
No-smoking advice,% 584 64.9 53.0–82.3
Healthy diet advice,% 1813 88.9 76.0–100
Written dietary advice,% 1083 60.1 41.2–85.3
Referred to a dietitian/nutritionist,% 632 34.9 22.8–49.1
Weight reduction advice (if BMI ≥30),% 1083 95.2 86.7–98.9
Physical activity advice (if no or light PA), % 373 83.8 56.2–100
Obesity (BMI ≥30) (n ¼ 3324)
No-smoking advice,% 969 65.7 43.4–79.7
Healthy diet advice,% 2978 89.9 64.3–99.7
Written dietary advice,% 1715 57.8 27.8–85.9
Referred to a dietitian/nutritionist,% 878 29.6 17.1–50.0
Weight reduction advice,% 3066 92.2 72.3–98.2
Physical activity advice (if no or light PA), % 701 82.9 64.7–96.4
Physical inactivity (n ¼ 1489)
Weight reduction advice (if BMI ≥30),% 787 92.9 76.4–100
Physical activity advice,% 1162 78.3 56.4–96.0
BMI ≥30, body mass index ≥30 kg/m
2. PA, physical activity. No PA, physical inactivity.
J.R. Banegas et al. 2148of obesity control. However, the EUROACTION study has shown
that a nurse-led, multi-disciplinary team approach can yield signiﬁ-
cant lifestyle improvements and risk factor reductions in coronary
patients and those at risk of developing CVD.
28 In addition, treated
dyslipidaemic women showed worse control, regardless of CVD
risk and country. This could be due to a less rigorous approach
towards women by clinicians, though earlier studies have reported
conﬂicting results.
29 Anyway, clinicians should make a speciﬁc point
of assessing risk factors in women.
Lastly, the between-country variation in attainment of treatment
targets may be due to differences in patients’ clinical and socio-
economic characteristics, in adherence to CVD prevention guide-
lines, and in healthcare systems between countries. Countries in
Eastern Europe showed generally lower than average attainment
of treatment goals for most CVD risk factors. Patients in Russia
had a lower than average level of drug treatment for hypertension
and dyslipidaemia, and this may partially explain the lower control
of BP and cholesterol. Also, a higher level of diabetes and physical
inactivity was observed in patients in Turkey, which may be related
to the lower control of obesity. Likewise, patients in Spain had a
higher proportion and lower control of dyslipidaemia than other
countries, and patients in Sweden had a higher proportion and
lower control of hypertension. The wide range of drug treatments
used across countries suggests important differences in drug pre-
scription policies or market penetration. Lifestyle interventions
also widely varied among countries. Improvement in smoking ces-
sation strategies, effective healthy diet advice, weight reduction
advice in obese patients, and physical activity advice may substan-
tially increase risk factors control in countries performing poorly.
Comparison with other studies
The EUROASPIRE III primary-prevention arm determined whether
the 2003 guidelines on CVD prevention were followed in high-risk
patients studied in 2006.
19,22 EURIKA, which assessed the 2007
European guidelines in 2010 in patients with a wide range of
CVD risk, found higher levels of hypertension and dyslipidaemia
control, but lower level of diabetes control than EUROASPIRE.
Nevertheless, no formal direct comparison can be made
between studies due to different patient populations and proto-
cols. In addition, EURIKA included determination of LDL choles-
terol, and not only total cholesterol in contrast with other major
cross-national initiatives.
16–19 The use of total cholesterol as the
only parameter for assessment of dyslipidaemia and the sole treat-
ment target overestimates the number of patients with lipids at
goal. This translates in practice into  1 million-treated dyslipidae-
mic patients who might be falsely considered to be adequately con-
trolled in the participating countries (data not shown), and may
preclude optimal treatment of patients in whom the LDL-c
remains uncontrolled.
Strengths and limitations
The use of common and standardized procedures for data collec-
tion allowed for a fair comparison of results across European
countries. The use of a central laboratory for blood analyses,
including LDL cholesterol and HbA1c, was also an important
strength of the EURIKA study in comparison with other similar
research initiatives.
16–19
...............................................................................................................................................................................
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Table 5 Sociodemographic and clinical characteristics associated with control of treated hypertension, dyslipidaemia,
type 2 diabetes, and obesity
Control of hypertension
(BP <140/90 mmHg)
a odds
ratio (95% CI)
Control of dyslipidaemia (TC
<5 and LDL-c <3 mmol/L)
a
odds ratio (95% CI)
Control of type 2 diabetes
(HbA1c <6.5%) odds ratio
(95% CI)
Control of obesity (BMI
<30 kg/m
2) odds ratio
(95% CI)
Gender
Women vs. men 1.13 (1.02–1.28) 0.67 (0.58–0.77) 1.00 (0.83–1.20) 1.09 (0.92–1.29)
Age
≥65 vs. 50–64
years
0.91 (0.78–1.05) 1.30 (1.12–1.52) 1.11 (0.90–1.37) 1.88 (1.65–2.14)
Cardiovascular risk factors
Smoking vs. no 1.02 (0.93–1.11) 0.90 (0.81–1.01) 0.94 (0.74–1.19) 1.30 (1.12–1.52)
Hypertension vs.
no
— 1.42 (1.13–1.78) 1.03 (0.86–1.22) 0.56 (0.46–0.68)
Dyslipidaemia
vs. no
1.27 (1.13–1.43) — 0.80 (0.63–0.99) 1.16 (1.02–1.32)
Type 2 diabetes
vs. no
0.20 (0.16–0.25) 1.03 (0.91–1.15) — 0.79 (0.68–0.92)
Obesity vs. no 0.80 (0.72–0.91) 1.12 (0.92–1.36) 1.13 (0.88–1.45) —
Physical
inactivity vs.
no
0.93 (0.76–1.14) 1.00 (0.75–1.33) 1.08 (0.82–1.42) 0.68 (0.54–0.85)
Generalized mixed linear model adjusted for all variables in table as appropriate, and for country (random effect variable).
CI, conﬁdence interval; BP, blood pressure; TC, total cholesterol; LDL-c, LDL cholesterol; HbA1c, glycated haemoglobin; BMI, body mass index.
aIf diabetes: blood pressure ,130/80 mmHg; or total cholesterol ,4.5 mmol/L and LDL ,2.5 mmol/L.
EURIKA study 2149A limitation of EURIKA is that the OneKey database, which is
the largest available database of practicing physicians in Europe,
is not statistically fully representative of all European physicians.
The percentage of physicians in the various participating countries
who are included on this database ranges from 10% in Russia to
50% in Spain. It is feasible that physicians participating in a study
of this nature may be more aware of and more successful at achiev-
ing treatment goals than those who did not participate. Even so, it
is clear that control of CVD risk factors can still be improved sub-
stantially. Also, the inclusion period was short (a few months), so
that frequent users of health services might have been over-
represented in the study sample. By the same token, less frequent
clinic attenders and ‘at risk’ patients with undetected risk factors
who have never attended for formal assessment are likely to be
underrepresented in our cohort. However, the large number of
practitioners included, the coverage of all relevant work-settings
involved in CVD prevention, and the random selection of study
patients suggest that EURIKA provides a comprehensive picture
of the status of primary CVD prevention in clinical practice
across Europe.
In addition, there is concern that the SCORE equation may
overestimate risk in many Western European countries with
decreasing secular trends in CVD mortality as well as in elderly
patients.
30 Conversely, the SCORE equation may underestimate
risk in Russia and other Eastern European countries that are
experiencing extremely high rates of CVD mortality. In particular,
in Russia the calculated CVD risk was lower than expected. This
was partially due to the fact that study participants in Russia had
the lowest mean age and the lowest percentage of men among
the EURIKA countries but also raises an important question
regarding the accuracy and representativeness of the current
SCORE system for CVD risk assessment in very high-risk
countries. Also, risk estimation in the elderly remains a challenge,
and the optimal threshold for deﬁning high CVD risk in those
≥65 years needs further investigation.
25,26
Lastly, we were only able to assess current level of residual risk
in relation to risk factor control in this cross-sectional survey of
patients with CVD risk factors. Additional work would be required
to address the important question of the effectiveness of risk
factor control in relation to the level of global risk at the time of
diagnosis or initiation of preventive treatment. However, we
have calculated that among the 2443 patients with a diagnosis of
hypertension or dyslipidaemia with complete information on systo-
lic BP and total cholesterol at diagnosis time (pre-treatment levels),
41% of treated hypertensive patients (26% of high risk and 45% of
low risk) were at BP goal, and 42% of treated dylipidaemic patients
(41% of high risk and 42% of low risk) were at LDL goal. Also,
though we do not know the time frame for risk factor treatment,
the mean duration of the current medication for most CVD risk
factors was 4–5 years, with rather narrow between-country
range (data not shown).
Clinical implications
The EURIKA study has shown that: (i) many patients with treated
CVD risk factors remained inadequately controlled, (ii) a large pro-
portion of patients achieving treatment goals for individual risk
factors remained at high-residual CVD risk, and (iii) lifestyle inter-
ventions are generally not well implemented. Finally, the large
...............................................................................................................................................................................
Table 6 Control of treated hypertension, dyslipidaemia, type 2 diabetes, and obesity in each country vs. the average
rate of control across the 12 participating countries
Control of
hypertension (BP <140/
90 mmHg)
a odds ratio
(95% CI)
Control of dyslipidaemia
(TC <5 and LDL-c
<3 mmol/L)
a odds ratio
(95% CI)
Control of type 2
diabetes (HbA1c <6.5%)
odds ratio (95% CI)
Control of obesity
(BMI <30 kg/m
2)
odds ratio (95% CI)
Country
AUS vs. average control 0.88 (0.67–1.15) 0.73 (0.51–1.04) 1.16 (0.71–1.91) 1.20 (0.81–1.77)
BEL vs. average control 1.30 (0.99–1.69) 1.69 (1.22–2.34) 1.66 (1.05–2.63) 1.27 (0.86–1.86)
FRA vs. average control 1.37 (1.04–1.79) 0.78 (0.56–1.10) 1.25 (0.77–2.03) 0.75 (0.48–1.18)
GER vs. average control 1.09 (0.84–1.40) 0.74 (0.52–1.04) 1.21 (0.78–1.87) 1.25 (0.85–1.83)
GRE vs. average control 1.68 (1.28–2.22) 0.88 (0.64–1.20) 1.38 (0.87–2.19) 1.82 (1.25–2.65)
NOR vs. average control 0.77 (0.58–1.02) 1.02 (0.72–1.44) 1.27 (0.77–2.10) 1.12 (0.73–1.74)
RUS vs. average control 0.76 (0.58–0.99) 0.38 (0.25–0.59) 0.63 (0.34–1.15) 0.94 (0.66–1.38)
SPA vs. average control 1.02 (0.77–1.33) 0.66 (0.48–0.92) 0.90 (0.56–1.44) 0.83 (0.54–1.26)
SWE vs. average control 0.76 (0.59–0.99) 1.20 (0.86–1.69) 0.54 (0.32–0.91) 0.94 (0.59–1.49)
SWI vs. average control 1.05 (0.80–1.36) 1.18 (0.85–1.65) 1.27 (0.81–1.99) 0.96 (0.64–1.45)
TUR vs. average control 0.71 (0.54–0.94) 0.62 (0.42–0.90) 0.62 (0.39–0.99) 0.59 (0.37–0.94)
UK vs. average control 1.03 (0.79–1.33) 3.03 (2.16–4.27) 0.68 (0.40–1.15) 0.45 (0.27–0.74)
Logistic regression models adjusted for sex and age.
CI, conﬁdence interval; BP, blood pressure; TC, total cholesterol; LDL-c, LDL cholesterol; HbA1c, glycated haemoglobin; BMI, body mass index.
AUS, Austria; BEL, Belgium; FRA, France; GER, Germany; GRE, Greece; NOR, Norway; RUS, Russia; SPA, Spain; SWE, Sweden; SWI, Switzerland. TUR, Turkey; UK, United
Kingdom.
aIf diabetes: blood pressure ,130/80 mmHg; or total cholesterol ,4.5 mmol/L and LDL-c (LDL cholesterol) ,2.5 mmol/L.
J.R. Banegas et al. 2150differences observed in risk factors control across countries
suggest additional room for improvement in countries performing
poorly. We support a more comprehensive application of the rec-
ommendations of the European guidelines for CVD primary pre-
vention to address the observed treatment gaps.
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An unusual heart
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In a female foetus of 31 weeks we diagnosed a mass
of 15 × 17 mm, occupying most of the left ventri-
cular cavity, which did not cause arrhythmia,
cardiac failure, or obstruction.
After birth, we conﬁrmed the presence of an
intraventricular mass and performed 3D echocar-
diography to highlight the spatial relationship with
cardiac structures.
The mass had an unusual heart shape and was
visibly smaller (13 × 12 mm) compared with the
prenatal aspect (Figure 1). There was no obstruction
to left ventricular inﬂow or outﬂow and basal ECG
was normal. The screening for tuberous sclerosis
was negative. The baby remained asymptomatic
during the hospitalization, but was readmitted 15
days later for the occurrence of runs of ventricular
tachycardia, discovered by Holter monitoring,
which we treated with beta-blockers.
During the foetal and neonatal period, rhabdo-
myomas represent the majority of cardiac
tumours and are closely associated with tuberous
sclerosis. Cardiac rhabdomyomas may be found in
asymptomatic patients and may be incidentally discovered during echocardiography, or may cause cardiac dysfunction requiring
medical and/or surgical intervention. On rare occasions, life-threatening conditions occur. These tumours generally regress after
birth, and cardiac-related problems are rare after the perinatal period. Regression in utero is rare: in a meta-analysis, Chao AS et al.
presented 266 cases of cardiac rhabdomyomas diagnosed with antenatal ultrasonography and only one regressed.
This contribution conﬁrms that the reduction of the mass size can start during foetal life and shows that the ﬁrst arrhythmic event
may occur several days after birth.
Panel A. Foetal echocardiography shows that the mass completely ﬁlls the left ventricular cavity.
Panel B. B-Mode postnatal echocardiography shows that the mass is adherent to the interventricular septum, has a heart shape form,
and its size has diminished.
Panel C. 3D transthoracic echocardiography highlights the heart shape form of the mass.
Panel D. Holter monitoring shows a run of non-sustained ventricular tachycardia.
M, mass; RA, right atrium; RV, right ventricle; LA, left atrium; LV, left ventricle; V, ventricular tachycardia.
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